Advertisement

Kardiopulmonale und mikrozirkulatorische Wirkungen von PGE1 nach intravenöser Gabe

  • J. H. Wilkens
  • H. Wilkens
  • J. C. Frölich

Zusammenfassung

Prostaglandin E1 (PGE1) hat bei Patienten mit akutem Atemnotsyndrom (ARDS) [16, 27, 29], pulmonaler Hypertonie [21], instabiler Angina pectoris [26] und peripherer arterieller Verschlußkrankheit (AVK) günstige therapeutische Wirkungen [6, 7]. Die Gründe für die therapeutische Wirksamkeit von PGE1 bei diesen Erkrankungen sind bisher nicht vollständig geklärt. Neben einer Verbesserung mikrozirkulatorischer Parameter [13] scheint PGE1 in niedriger Dosierung selektive relaxierende Wirkung auf kontraktile Lungenelemente zu haben [21]. Verbesserung der myokardialen Funktion, der peripheren Durchblutung und des pulmonalen Gasaustauschs sind bei den oben genannten Erkrankungen oft von entscheidender Bedeutung. Informationen über die Dosis-Wirkungsbeziehung von PGE1 auf kardiale, pulmonale und mikrozirkulatorische Parameter sind für den sinnvollen therapeutischen Einsatz unerläßlich.

Literatur

  1. 1.
    Arnaudov K, Faust U (1985) A microprocessor based system for long term registration of the impedancecardiogram and the systolic time intervals. Med Prog Technol 10: 229–238PubMedGoogle Scholar
  2. 2.
    Barnes PJ, Gribbin HR, Osmanliev D, Pride NB (1981) Partial flow-volume curves to measure bronehodilator dose-response curves in normal humans. J Appl Physiol 50 (6): 1193–1197PubMedGoogle Scholar
  3. 3.
    Boudoulas H, Schaa SF, Lewis RP, Welch TG, Degreen P, Kates RE (1977) Negative inotropic effects of lidocaine in patients with coronary arterial disease and normal subjects. Chest 71: 170–174CrossRefPubMedGoogle Scholar
  4. 4.
    Bouhuys A, Hunt VR, Kim BM, Zapletal A (1969) Maximum exspiratory flow rates in induced bronchoconstriction in man. J Clin Invest 48: 1159–1168CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Brecht T, Ayaz M (1985): Circulation parameters during intravenous and intraarterial administration of increasing doses of Prostaglandin E1 in healthy subjects. Klin Wochenschr 63: 1201–1204CrossRefPubMedGoogle Scholar
  6. 6.
    Carlson LA, Olsson AG (1976) Intravenous Prostaglandin E1 in severe peripheral vascular disease. Lancet 2: 810CrossRefPubMedGoogle Scholar
  7. 7.
    Creutzig A, Caspary L, Alexander K (1986) Prospective open pilot study to investigate the effect of intermittent intra-arterial infusion treatment with Prostaglandin E1 in patients with intermittent claudication. In: Prostaglandins in Atherosclerosis. Sinziger H, Rogatti W (eds), Springer, BerlinGoogle Scholar
  8. 8.
    Cuthbert MF (1969) Effect on airway resistance of Prostaglandin E1 given by aerosol to healthy and asthmatic volunteers. Brit Med J 4: 723–726CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ewald U, Rooth G, Tuvemo (1981) Postischemic hyperemia studied with a transcutaneous oxygen electrode at 33–37 °C. Scand J Clin Lab Invest. 41, 641Google Scholar
  10. 10.
    Göthgen I, Jacobsen E (1978) Trancutaneous oxygen tension measurement. I: Age Variation and reproducability. Acta Anaesthesiol Scand suppl 67: 66–70CrossRefPubMedGoogle Scholar
  11. 11.
    Hargreave FE, Ryan G, Thomson NC (1981) Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. J Allergy Clin Immunol. 68 (5): 347–355CrossRefPubMedGoogle Scholar
  12. 12.
    Harris WS, Schoenfeld CD, Weissler AM (1967) Effects of adrenergic reeeptor activation and blockade on the systolic pre-ejection period, heart rate and arterial pressure in man. J Clin Invest 56: 1704–1714CrossRefGoogle Scholar
  13. 13.
    Heidrich H, Lammersen T (1985) Vitalkapillarmikroskopische Untersuchungen und trans-kutane p02-Messungen bei intravenöser Prostaglandin E1 Infusion. Dtsch Med Wochenschr 110: 1283–1285CrossRefPubMedGoogle Scholar
  14. 14.
    Herxheimer H, Roetscher I (1971) Effects of Prostaglandin E1 on lung funetion in bronchial asthma. Eur J Clin Pharmacol 3: 23–125CrossRefGoogle Scholar
  15. 15.
    Hoffarth HP, Reier W, Ulmer WT (1987) Gasaustauschstörungen bei inhalativer Provokation. A temw. -Lungenkrkh 13 (7): 294–297Google Scholar
  16. 16.
    Holcroft JW, Vassar MJ, Weber CJ (1985) Prostaglandin E and survival of patients with the adult respiratory distress Syndrome. Ann Surg 203 (4): 371–78Google Scholar
  17. 17.
    Kowalski J, Möllmann H, Holtmann, Hoffarth HP, Ulmer WT (1986) Kontinuierliche transkutane O2-Registrierung und gleichzeitige fortlaufende bronchiale Strömungswider-standsmessung unter inhalativer Allergenprovokation. Atemw-Lungenkrkh 12 (6): 254–256Google Scholar
  18. 18.
    Lilliefors WH (1967) On the Kolmogorov-Smirnow test for normality with mean and variance unknown. J Am Statistical Association 64: 399–402CrossRefGoogle Scholar
  19. 19.
    Marascuilo LA, McSweeny M (1977) Nonoparametric and distribution free methods for social science. Wadsworth Publishing, Belmont, CA, USAGoogle Scholar
  20. 20.
    Mohapatra SN (1981) Non-invasive cardiovascular monitoring by electrical impedance technique. Pitman Medical, LondonGoogle Scholar
  21. 21.
    Naeje N, Melot C, Hallemans R (1982) Reduction in pulmonary hypertension by Prosta-glandin E1 in decompensated chronic obstructive pulmonary disease. Am Rev Resp Dis 125: 1–5Google Scholar
  22. 22.
    Naeje N, Bracamonte M, Sergijsels R (1983) Influence of parenteral Prostaglandin E1 on lung mechanics in normal man. Eur J Clin Pharmacol 24: 329–332CrossRefGoogle Scholar
  23. 23.
    Nakano J, McCurdy JR (1967) Cardiovascular effects of PGE1. J Pharm Exp Ther 156 (3): 538–547Google Scholar
  24. 24.
    Rousson D, Galleyrand J, Sillie M, Boissel (1987) Uncorrected pre-ejection period: A simple non-invasive measurement for pharmacodynamic Screening of inotropic activity. Eur J Clin Pharmacol 31: 559–562CrossRefPubMedGoogle Scholar
  25. 25.
    Rooth G, Hedstrand U, Tyden H, Ögren C (1976) The validity fo transcutaneous oxygen tension measurements in adults. Crit care Med 4: 162–5CrossRefPubMedGoogle Scholar
  26. 26.
    Siegel RJ, Prediman KS, Nathan M, Rodriguez L, Shell WE (1984) Prostaglandin E1 infusion in unstable angina: Effects on anginal frequency and cardiac function. Am Heart Journal 108 (4): 863–868CrossRefGoogle Scholar
  27. 27.
    Shoemaker WC, Appel PL (1986) Effects of Prostaglandin E1 in adult respiratory distress Syndrome. Surgery 99 (3): 275–83PubMedGoogle Scholar
  28. 28.
    Talley RC, Meyer JF, MacNay JL (1971) Evaluation of the pre-ejection period as an estimate of myocardial contractility in dogs. Am J Cardiol 27, 384CrossRefPubMedGoogle Scholar
  29. 29.
    Tokioka H, Kobayashi O, Ohta Y, Wakabayashi T, Kosaka F (1985) The acute effects of Prostaglandin E1 on the pulmonary circulation and oxygen delivery in patients with the adult respiratory distress Syndrome. Intensive care Med 11: 61–64CrossRefPubMedGoogle Scholar
  30. 30.
    Zamel N (1984) Partial Flow Volume Curves. Bull Eur Physiopathol Respir 20: 471–475PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • J. H. Wilkens
  • H. Wilkens
  • J. C. Frölich

There are no affiliations available

Personalised recommendations